Despite the well-documented impact of KEAP1 and NFE2L2 mutations in NSCLCs and LCNEC [34], the prognostic role of KEAP1 methylation in lung cancer has not yet been clarified. Here, NFE2L2 is linked to large cell neuroendocrine carcinoma.